Janel Long-Boyle

Janel Long-Boyle is a translational scientist at the University of California San Francisco (UCSF), focusing on pediatric cancer therapeutics, pharmacokinetics, and clinical trial design within the context of hematopoietic cell transplantation (HCT). Her work explores how age, renal function, and genetic variants affect drug clearance in pediatric HCT patients.

• Education: BS in Biochemistry (2000), PharmD (2006), PhD in Experimental and Clinical Pharmacology (2009) from the University of Minnesota.

Her research spans pharmacogenomics, immunosuppressive agents, and toxicity monitoring in HCT. Publications from 2021–2025 highlight expertise in busulfan dosing, transplant complications, and neonatal neuroprotection studies.

• Scientific Awards:
  • Early Career Research Award (2010)
  • Travel Award for Early Career Researchers (2011)
  • NIH Loan Repayment Recipient (2011, 2013)
  • Gary Rifkind Research Award (2012)
  • Mid-Career Travel Award (2017)

Dr. Long-Boyle’s collaborations include UCSF, international pediatric transplant centers, and cross-disciplinary teams in pharmacology and hematology.